BERLIN, Germany, 4 June 2024 – MGI (MGI Tech Co., Ltd. or its subsidiaries, collectively referred to as MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the opening of its new European headquarters in Berlin to support the life science community across the region.
“We chose Berlin for our European headquarters because of its vibrant and dynamic environment, ensuring accessibility for partners, collaborators, and customers,” said Dr. Yong Hou, General Manager of MGI Europe and Africa. “I eagerly anticipate the innovative collaborations and discoveries ahead.”
Equipped with MGI’s full product portfolio, the Customer Experience Center (CEC) within the Berlin headquarters serves as a dedicated gateway for researchers and scientists to learn about and experience the company’s cutting-edge life science innovations. Through tailored training, demonstrations, and hands-on workflows, visitors can explore the full potential of creating their own innovative multi-omics tools based on proprietary DNBSEQ™ technology. The inaugural initiative launched at the CEC opening is the G400 Developer Program, designed to support European researchers in developing and implementing customised workflows for spatial transcriptomics, multiplex immunofluorescence (mIF), and other multi-omics analyses.
The facility is configured with DNA sequencing, Cell Omics, and Spatial Omics capabilities to support novel applications and project development for MGI customers and collaborators. Conveniently located near Berlin Brandenburg Airport and open to external visits, the space spans over 600 square metres and features advanced labs alongside the CEC. It will also house prototypes of upcoming MGI products for early access and testing by European partners.
Following a strong start to the year, MGI continues to expand its presence and better serve the life science sector through groundbreaking partnerships across Europe. In February, the company entered a collaboration agreement with MetaGenoPolis in France, equipping the organisation with MGI’s DNBSEQ-T7 ultra-high throughput sequencer for the Le French Gut project and other research under the Million Microbiomes from Humans Project (MMHP).
In March, MGI achieved a milestone partnership with Eurofins Genomics Europe Genotyping A/S, marking the first corporate order of the revolutionary DNBSEQ-T20×2 ultra-high throughput sequencer in Europe and paving the way for advances in precision health initiatives across the continent. More recently, MGI showcased its life science offerings, including lab automation and sequencing products, at ECCMID 2024, and announced a technical assessment of ABL DeepChek® assays on its DNBSEQ-G400 and DNBSEQ-G99 platforms. Further verification and validation studies of DeepChek® assays will also be conducted on the newly launched DNBSEQ-E25.
“We have experienced positive growth and established many valuable partnerships in the region in recent years. Establishing our new European headquarters will enable us to sustain this momentum and empower more users,” said Duncan Yu, President at MGI. “We look forward to further advancements by providing an optimal customer experience and facilitating collaboration for greater omics access and capabilities across Europe and globally.”
